Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 4;69(6):e0175524.
doi: 10.1128/aac.01755-24. Epub 2025 Apr 23.

Plasmodium falciparum Kelch-13 artemisinin partial resistance markers in Fort Portal, Western Uganda, 2024

Affiliations

Plasmodium falciparum Kelch-13 artemisinin partial resistance markers in Fort Portal, Western Uganda, 2024

Welmoed van Loon et al. Antimicrob Agents Chemother. .

Abstract

In Fort Portal, Uganda, artemisinin resistance-associated mutations in Plasmodium falciparum Kelch13 (n = 126) were present in 4.8% (675V, 561H, and 441L). A mutation of unknown relevance, 490T, occurred in 9.5%. PfMDR1 variants suggested increased lumefantrine tolerance (N86, 100%). Mutation 500N was absent, and 199S occurred in 12.8%. The latter is of unknown relevance. These data indicate an incipient emergence of artemisinin resistance in a crucial location between Rwandan and Ugandan resistance hotspots and hardly affected DR Congo.

Keywords: PfK13; PfMDR1; Uganda; artemisinin resistance; molecular markers of resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Occurrence of validated and associated PfK13 markers of artemisinin partial resistance in East Africa, 2020–2023, color-coded by majority markers. Colored circles indicate regions where validated or candidate PfK13 markers have been identified at prevalence >10% in 2020–2023. Yellow, majority of PfK13 mutations found are 675V and/or 469Y (2); purple, majority PfK13-561H (2, 10, 12, 13); blue, majority PfK13-441L (2); and brown, majority PfK13-469F (2). Background map created with mapchart.net.

References

    1. World Health O. 2023. World malaria report 2023. World Health Organization, Geneva.
    1. Conrad MD, Asua V, Garg S, Giesbrecht D, Niaré K, Smith S, Namuganga JF, Katairo T, Legac J, Crudale RM, Tumwebaze PK, Nsobya SL, Cooper RA, Kamya MR, Dorsey G, Bailey JA, Rosenthal PJ. 2023. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N Engl J Med 389:722–732. doi:10.1056/NEJMoa2211803 - DOI - PMC - PubMed
    1. Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, Nair S, White MM, Dziekan J, Ling C, Proux S, Konghahong K, Jeeyapant A, Woodrow CJ, Imwong M, McGready R, Lwin KM, Day NPJ, White NJ, Nosten F. 2016. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar Border (2003-2013): the role of parasite genetic factors. Clin Infect Dis 63:784–791. doi:10.1093/cid/ciw388 - DOI - PMC - PubMed
    1. van der Pluijm RW, Tripura R, Hoglund RM, Pyae Phyo A, Lek D, Ul Islam A, Anvikar AR, Satpathi P, Satpathi S, Behera PK, et al. . 2020. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet 395:1345–1360. doi:10.1016/S0140-6736(20)30552-3 - DOI - PMC - PubMed
    1. Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, Legac J, Garg S, Giesbrecht D, Smith SR, Ceja FG, Nsobya SL, Bailey JA, Cooper RA, Rosenthal PJ. 2022. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun 13:6353. doi:10.1038/s41467-022-33873-x - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources